Physician profile
Jeffrey Jon Hansen
NPI 1356410419
$2,759,762.67
in general payments reported to CMS, 2019-2025
27 companies · $492K in 2025
The $492K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359K · 2020: $222K · 2021: $370K · 2022: $422K · 2023: $433K · 2024: $463K · 2025: $492K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $987K · Travel and Lodging: $207K · Consulting Fee: $132K · Food and Beverage: $34K · Honoraria: $28K · Education: $24.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $987,078.05 |
| Travel and Lodging | $206,594.34 |
| Consulting Fee | $132,110.50 |
| Food and Beverage | $34,327.64 |
| Honoraria | $27,775.00 |
| Education | $24.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625,268.60 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $546,755.27 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $319,594.91 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $278,506.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $271,551.55 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Allergan, INC. | $233,049.86 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169,634.24 | 2020-2025 | Caplyta |
| Alkermes, INC. | $93,749.77 | 2020-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $82,812.27 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $39,754.22 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $33,056.71 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $23,865.60 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $19,493.50 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $11,950.38 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $3,344.66 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,326.66 | 2020-2021 | |
| Corium, LLC | $2,326.65 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $1,702.22 | 2020-2022 | |
| Lundbeck LLC | $432.43 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $198.29 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $144.62 | 2019-2024 | Spravato |
| Noven Therapeutics, LLC | $71.57 | 2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $69.25 | 2019 | |
| Collegium Pharmaceutical, INC. | $29.14 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $27.64 | 2020 | |
| Bausch Health US, LLC | $24.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.